[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX347083B - Forma de dosificacion. - Google Patents

Forma de dosificacion.

Info

Publication number
MX347083B
MX347083B MX2013006523A MX2013006523A MX347083B MX 347083 B MX347083 B MX 347083B MX 2013006523 A MX2013006523 A MX 2013006523A MX 2013006523 A MX2013006523 A MX 2013006523A MX 347083 B MX347083 B MX 347083B
Authority
MX
Mexico
Prior art keywords
dosage form
matrix
present
melt extruded
cns
Prior art date
Application number
MX2013006523A
Other languages
English (en)
Other versions
MX2013006523A (es
Inventor
Mohammad Hassan
Original Assignee
Euro-Celtique S A *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro-Celtique S A * filed Critical Euro-Celtique S A *
Publication of MX2013006523A publication Critical patent/MX2013006523A/es
Publication of MX347083B publication Critical patent/MX347083B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29B—PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS
    • B29B9/00—Making granules
    • B29B9/12—Making granules characterised by structure or composition

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Mechanical Engineering (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona una forma de dosificación, particularmente, una forma de dosificación resistente al abuso; que comprende partículas extruidas por fusión no alteradas que comprenden un fármaco seleccionado de un agonista opioide, un tranquilizante, un depresivo del CNS, un estimulante del CNS o un hipnótico sedante; y una matriz; en donde las partículas extruidas por fusión están presentes como una fase discontinua en la matriz.
MX2013006523A 2010-12-09 2011-12-09 Forma de dosificacion. MX347083B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1020895.7A GB201020895D0 (en) 2010-12-09 2010-12-09 Dosage form
PCT/GB2011/052455 WO2012076907A2 (en) 2010-12-09 2011-12-09 Dosage form

Publications (2)

Publication Number Publication Date
MX2013006523A MX2013006523A (es) 2014-02-27
MX347083B true MX347083B (es) 2017-04-11

Family

ID=43566928

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013006523A MX347083B (es) 2010-12-09 2011-12-09 Forma de dosificacion.

Country Status (30)

Country Link
US (1) US20130330409A1 (es)
EP (1) EP2648699B1 (es)
JP (1) JP5926738B2 (es)
KR (1) KR101946037B1 (es)
CN (2) CN107397720A (es)
AU (1) AU2011340288B2 (es)
BR (1) BR112013014361A2 (es)
CA (1) CA2820431C (es)
CO (1) CO6751243A2 (es)
CY (1) CY1119050T1 (es)
DK (1) DK2648699T3 (es)
EA (1) EA024509B1 (es)
ES (1) ES2626676T3 (es)
GB (1) GB201020895D0 (es)
HR (1) HRP20170650T1 (es)
HU (1) HUE033340T2 (es)
IL (1) IL226437A0 (es)
LT (1) LT2648699T (es)
ME (1) ME02687B (es)
MX (1) MX347083B (es)
MY (1) MY161845A (es)
NZ (1) NZ610921A (es)
PL (1) PL2648699T3 (es)
PT (1) PT2648699T (es)
RS (1) RS55976B1 (es)
SG (1) SG190356A1 (es)
SI (1) SI2648699T1 (es)
UA (1) UA111834C2 (es)
WO (1) WO2012076907A2 (es)
ZA (1) ZA201304158B (es)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
EP1610767B1 (en) 2003-03-26 2011-01-19 Egalet A/S Morphine controlled release system
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
JP5774853B2 (ja) 2008-01-25 2015-09-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 医薬投薬形
EP2393484A1 (en) 2009-02-06 2011-12-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
PE20121067A1 (es) 2009-07-22 2012-09-05 Gruenenthal Chemie Forma de dosificacion de liberacion controlada extruida por fusion en caliente
WO2011009604A1 (en) 2009-07-22 2011-01-27 Grünenthal GmbH Oxidation-stabilized tamper-resistant dosage form
WO2011141489A1 (en) 2010-05-10 2011-11-17 Euro-Celtique S.A. Manufacturing of active-free granules and tablets comprising the same
JP5840201B2 (ja) 2010-05-10 2016-01-06 ユーロ−セルティーク エス．エイ． 活性剤を負荷した顆粒と追加の活性剤の組合せ
NZ700732A (en) 2010-05-10 2015-08-28 Euro Celtique Sa Pharmaceutical compositions comprising hydromorphone and naloxone
WO2012028318A1 (en) 2010-09-02 2012-03-08 Grünenthal GmbH Tamper resistant dosage form comprising an anionic polymer
RU2604676C2 (ru) 2010-09-02 2016-12-10 Грюненталь Гмбх Устойчивая к разрушению лекарственная форма, содержащая неорганическую соль
AR087359A1 (es) 2011-07-29 2014-03-19 Gruenenthal Gmbh Tableta a prueba de alteracion que proporciona liberacion inmediata del farmaco
CN103841964A (zh) 2011-07-29 2014-06-04 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
MX356421B (es) 2012-02-28 2018-05-29 Gruenenthal Gmbh Forma de dosificacion resistente a la manipulacion indebida que comprende un compuesto farmacologicamente activo y un polimero anionico.
DK2838512T3 (en) 2012-04-18 2018-11-19 Gruenenthal Gmbh MANIPULATED AND DOSAGE DUMPED PHARMACEUTICAL DOSAGE FORM
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
KR20150059167A (ko) 2012-07-06 2015-05-29 에갈렛 리미티드 제어된 방출을 위한 남용 제지 약학적 조성물
EP2872121B1 (en) 2012-07-12 2018-09-05 SpecGx LLC Extended release, abuse deterrent pharmaceutical compositions
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014191397A1 (en) 2013-05-29 2014-12-04 Grünenthal GmbH Tamper-resistant dosage form containing one or more particles
AR096438A1 (es) * 2013-05-29 2015-12-30 Gruenenthal Gmbh Forma de dosificación resistente al uso indebido con perfil de liberación bimodal, proceso
JP6449871B2 (ja) 2013-07-12 2019-01-09 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング エチレン−酢酸ビニルポリマーを含有する改変防止剤形
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
AU2014350135B2 (en) 2013-11-13 2017-08-31 Euro-Celtique S.A. Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
WO2015071248A1 (en) 2013-11-15 2015-05-21 Synthon B.V. Abuse-proofed extended release pharmaceutical composition comprising tapentadol
JP6480936B2 (ja) 2013-11-26 2019-03-13 グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング クライオミリングによる粉末状医薬組成物の調製
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2938699A1 (en) * 2014-02-05 2015-08-13 Kashiv Pharma Llc Abuse-resistant drug formulations with built-in overdose protection
WO2015145461A1 (en) * 2014-03-26 2015-10-01 Sun Pharma Advanced Research Company Ltd. Abuse deterrent immediate release biphasic matrix solid dosage form
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
CN106456550A (zh) 2014-05-26 2017-02-22 格吕伦塔尔有限公司 避免乙醇剂量倾泻的多颗粒
US9707184B2 (en) 2014-07-17 2017-07-18 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
WO2016016431A1 (en) * 2014-08-01 2016-02-04 Krka, D.D., Novo Mesto Pharmaceutical formulation comprising an opioid agonist and an opioid antagonist prepared by melt granulation using lipid esters
EP3209282A4 (en) 2014-10-20 2018-05-23 Pharmaceutical Manufacturing Research Services, Inc. Extended release abuse deterrent liquid fill dosage form
BR112017021475A2 (pt) 2015-04-24 2018-07-10 Gruenenthal Gmbh forma de dosagem resistente à adulteração (tamper) com liberação imediata e resistência contra extração de solvente
WO2016170094A1 (en) * 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant fixed dose combination providing fast release of two drugs from particles
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
WO2017194576A1 (en) * 2016-05-13 2017-11-16 Merck Patent Gmbh Hot melt extrusion composition using direct compressible excipient as plasticizer
EP3481378A1 (en) 2016-07-06 2019-05-15 Grünenthal GmbH Reinforced pharmaceutical dosage form
WO2018118902A1 (en) 2016-12-19 2018-06-28 The Regents Of The University Of California Dual-enzyme responsive peptides
US11541125B2 (en) 2016-12-19 2023-01-03 The Regents Of The University Of California Noncrushable pill formulations
TW201940171A (zh) * 2018-02-08 2019-10-16 景凱生物科技股份有限公司 類鴉片受體拮抗劑之固體劑型用之醫藥劑型

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2653337B1 (fr) 1989-10-23 1992-02-07 Dow Corning Sa Element a liberation prolongee et procede pour le fabriquer.
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
MXPA05010636A (es) * 2003-04-04 2005-12-12 Pharmacia Corp Comprimidos de multiparticulas preparados por compresion de liberacion oral prolongada.
US7201920B2 (en) * 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0403098D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Extrusion
GB0403100D0 (en) * 2004-02-12 2004-03-17 Euro Celtique Sa Particulates
TWI350762B (en) * 2004-02-12 2011-10-21 Euro Celtique Sa Particulates
DE102004032049A1 (de) * 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
CN101132772B (zh) * 2005-01-28 2012-05-09 欧洲凯尔特公司 耐醇剂型
WO2008027442A2 (en) * 2006-08-30 2008-03-06 Theraquest Biosciences, Llc Abuse deterrent oral pharmaceutical formulations of opioid agonists and method of use
DE102007011485A1 (de) * 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
GB0909680D0 (en) * 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form

Also Published As

Publication number Publication date
AU2011340288B2 (en) 2016-09-15
HUE033340T2 (en) 2017-11-28
GB201020895D0 (en) 2011-01-26
ES2626676T3 (es) 2017-07-25
EP2648699B1 (en) 2017-03-01
KR20130126955A (ko) 2013-11-21
CA2820431A1 (en) 2012-06-14
CN107397720A (zh) 2017-11-28
SI2648699T1 (sl) 2017-05-31
PT2648699T (pt) 2017-06-05
CA2820431C (en) 2020-11-03
IL226437A0 (en) 2013-07-31
WO2012076907A3 (en) 2012-09-07
UA111834C2 (uk) 2016-06-24
EA201390848A1 (ru) 2013-12-30
KR101946037B1 (ko) 2019-02-08
JP5926738B2 (ja) 2016-05-25
EA024509B1 (ru) 2016-09-30
JP2013544875A (ja) 2013-12-19
RS55976B1 (sr) 2017-09-29
HRP20170650T1 (hr) 2017-06-30
CY1119050T1 (el) 2018-01-10
EP2648699A2 (en) 2013-10-16
US20130330409A1 (en) 2013-12-12
SG190356A1 (en) 2013-06-28
DK2648699T3 (en) 2017-06-06
AU2011340288A1 (en) 2013-06-13
MY161845A (en) 2017-05-15
CN103282026A (zh) 2013-09-04
MX2013006523A (es) 2014-02-27
LT2648699T (lt) 2017-05-25
ZA201304158B (en) 2014-12-23
BR112013014361A2 (pt) 2016-09-27
CO6751243A2 (es) 2013-09-16
NZ610921A (en) 2015-02-27
WO2012076907A2 (en) 2012-06-14
ME02687B (me) 2017-06-20
PL2648699T3 (pl) 2017-07-31

Similar Documents

Publication Publication Date Title
MY161845A (en) Dosage form
MY173629A (en) Dosage form
HK1214984A1 (zh) 給藥管理系統和方法
TN2011000160A1 (en) Combination of an insulin and a glp -1 agonist
EP4252801A3 (en) Chemical engines and methods for their use, especially in the injection of highly viscous fluids
WO2009074300A3 (en) Hedgehog pathway antagonists and therapeutic applications thereof
BR112012024139A2 (pt) formulações farmacêuticas de camada dupla contendo agonistas e antagonistas de opióide.
HK1160762A1 (zh) 料盒、用於固體藥物部分的藥物分配器以及它們的使用
BRPI0924190A2 (pt) gabinete para medicação, conjunto de gavetas e sistema de distribuição
EP2286337A4 (en) SORTING THE IMPORTANCE OF ALARMS FOR PROBLEMS IN LARGE SYSTEMS
EP2115690A4 (en) METHOD AND SYSTEM FOR CONTEXTUAL MEDICAMENT DOSING
BRPI1010768A2 (pt) composto, e, composição farmacêutica.
PT2560713E (pt) Distribuidor de seringa, suporte e placa de aplicação para o referido distribuidor de seringa e processo para a sua utilização
GB201004728D0 (en) Methods, apparatus and systems configured for heterogeneous secure associations in wi-fi pan
BRPI0914306A2 (pt) método e sistema para implantação de cobrança telefônica para incentivar o uso de telefone compartilhado.
CL2014003525A1 (es) Composicion farmaceutica que comprende fimasartan, hidroclorotiazida y un aglutinante; procedimiento de preparacion; su uso en el tratamiento de hipertension.
IL199923A0 (en) Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
BRPI0820361A2 (pt) Adaptador para cânulas para dispensar produtos, e cânula.
BR112012002311A2 (pt) composto, composição farmacêutica, e, uso do composto.
PL2586424T3 (pl) Kompozycje farmaceutyczne zawierające antagonistę receptora angiotensyny II, hydrochlorotiazyd i środek rozsadzający
EP2776054A4 (en) ANTAGONISTS FOR THE ORIGINAL VASOPRESSIN V2 RECEPTOR AND ITS USES
UA106478C2 (uk) Комбінація інсуліну і агоніста glp-1
EP2627652A4 (en) NEW PYRIDYLBENZOXAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITION THEREFOR AND USE THEREOF
ZA200801724B (en) An improved monolithic drug delivery system

Legal Events

Date Code Title Description
FG Grant or registration